comparemela.com

Latest Breaking News On - 888 holdings plc - Page 1 : comparemela.com

Stock Analysts Updated EPS Estimates for December 4th (888, CPG, DS, EOSE, FDEV, FUTR, PTEC, PZC, SMDS, SYNC)

Stock Analysts’ updated eps estimates for Monday, December 4th: 888 (LON:888) had its hold rating reissued by analysts at Numis Securities Ltd. Compass Group (LON:CPG) had its buy rating reissued by analysts at Numis Securities Ltd. Drive Shack (LON:DS) was upgraded by analysts at Barclays PLC to an overweight rating. They currently have GBX 360 […]

Reata Pharmaceuticals (RETA) Reiterates Rating Reiterated at 888

Reata Pharmaceuticals (NASDAQ:RETA – Free Report)‘s stock had its “reiterates” rating reiterated by equities researchers at 888 in a research report issued on Wednesday, Benzinga reports. RETA has been the subject of a number of other reports. Stifel Nicolaus lifted their price objective on Reata Pharmaceuticals from $105.00 to $115.00 and gave the company a […]

California Water Service Group (NYSE:CWT) Receives Upgrade Rating from 888

California Water Service Group (NYSE:CWT – Free Report)‘s stock had its “upgrade” rating restated by 888 in a research report issued to clients and investors on Wednesday, Benzinga reports. Other equities research analysts have also issued reports about the company. Wells Fargo & Company upgraded California Water Service Group from an “underweight” rating to an […]

Reata Pharmaceuticals (NASDAQ:RETA) Stock Rating Reaffirmed by 888

Reata Pharmaceuticals (NASDAQ:RETA – Free Report)‘s stock had its “reiterates” rating reiterated by analysts at 888 in a research note issued to investors on Wednesday, Benzinga reports. A number of other equities analysts also recently weighed in on the stock. SVB Securities raised shares of Reata Pharmaceuticals from a “market perform” rating to an “outperform” […]

Reata Pharmaceuticals (NASDAQ:RETA) Receives Reiterates Rating from 888

888 reiterated their reiterates rating on shares of Reata Pharmaceuticals (NASDAQ:RETA – Free Report) in a research report released on Wednesday, Benzinga reports. RETA has been the subject of several other research reports. LADENBURG THALM/SH SH raised their price objective on shares of Reata Pharmaceuticals from $104.00 to $122.00 in a research note on Thursday. […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.